Bleomycine Bij Vergevorderde Ziekte Van Hodgkin

Summary

The therapeutic value and the toxicity of bleomycin have been evaluated in ten patients with advanced Hodgkin’s disease. A bleomycin therapy—particularly in advanced cases—is indicated in case of resistance to other forms of chemotherapy or their contra-indication because of marrow suppression. The therapeutic effect is limited. The short remission period and the toxicity make bleomycin unsuitable for a maintenance therapy. The severe skin toxicity and the perilous Iungfibrosis as a result of a bleomycin therapy are extensively dealt with.

Key Words:

• Bleomycin
• advanced Hodgkin